Another analysis based on VigiBase data indicated that 91.8% of cases were new-onset IBD, and approximately three-quarters of IBD relapse cases were detected within 3 months of starting anti-IL-17 therapy (Petitpain et al., 2021). Here, IL17A is linked to inflammatory bowel disease.